Children with neuroblastoma receiving high-dose carboplatin as part of their conditioning regimen for autologous marrow transplantation have a high incidence of speech frequency hearing loss. We evaluated hearing loss in 11 children with advanced stage neuroblastoma who underwent autologous marrow transplantation, following a conditioning regimen containing high-dose carboplatin (2 g/m 2 , total dose). Audiometric evaluations were obtained at diagnosis, prior to and following transplant. Exposure to other known ototoxins also was assessed. All patients sustained worsening of hearing following high-dose carboplatin. Nine of the 11 children (82%) had evidence of speech frequency hearing loss post transplant for which hearing aids were recommended (grades 3-4). Three of the nine children had speech frequency loss prior to transplant which progressed following transplant. The entire group was heavily pre-treated with platinum-containing chemotherapy pre-BMT and had extensive exposure to other ototoxins, including aminoglycoside antibiotics, diuretics, and noise exposure -all of which could have exacerbated the effects of carboplatin. High-dose carboplatin is ototoxic, particularly in patients who have been primed with previous platinum therapy or other ototoxic agents. We conclude that further efforts are needed to monitor and minimize this complication. In cases where hearing loss is inevitable due to cumulative ototoxic exposures, families need to be adequately prepared for the tradeoffs of potentially curable therapy. Keywords: ototoxicity; neuroblastoma; carboplatin The platinum-containing chemotherapeutic agents play a key role in the treatment of selected pediatric solid tumors. Carboplatin (cis-diammine I, I-cyclobutane dicarboxylato platinum II (CBDCA)), an analogue of cisplatin (cis-dichlorodiammine platinum II (CDDP)), was introduced to clini- 1 Early reports indicated that the incidence of ototoxicity following carboplatin administration might also be lower than that after cisplatin use.
cal trials in 1981 based on encouraging responses in antitumor activity but less nephrotoxicity than cisplatin. 1 Early reports indicated that the incidence of ototoxicity following carboplatin administration might also be lower than that after cisplatin use. [1] [2] [3] These studies revealed that myelosuppression, not nephrotoxicity, was the dose-limiting toxicity for carboplatin. At the maximum tolerable doses for myelosuppression, single-agent phase I and II studies of carboplatin in adults found a 15% incidence of subclinical hearing loss and a 1% incidence of clinical ototoxicity, primarily manifested as tinnitus. 2, 3 Similarly, severe hearing loss in children was relatively infrequent. 4 In contrast, the reported incidence of ototoxicity with cisplatin, administered at conventional doses, has ranged from 4 to 91% in different studies. 5 Moreover, when hearing loss occurs, it is predominantly in the high-frequency range, although speech frequencies are also affected -occasionally independent of dose or dose rate. The overall incidence of high-frequency hearing loss following cisplatin administration ranges from 30 to 50%; progressive involvement of the speech range frequencies has been reported at 15-20%. 6 Generally, these losses are irreversible, 7 although rare reports describe partial recovery over a period of years. 8 An abnormal pre-treatment audiogram, 6 prior cranial radiation 9, 10 and increasing cumulative dose of cisplatin [11] [12] [13] have been consistently predictive of an increased risk of subsequent hearing loss. The role of age, renal function, mode of administration (infusion vs bolus) and concurrent use of other ototoxic agents is less clear. 6, 9, [11] [12] [13] Recently, the myelotoxicity of carboplatin has been overcome by the use of autologous stem cell rescue and/or the use of hematopoietic growth factors, resulting in the use of higher doses of drug to increase anti-tumor efficacy. The impact of higher doses of carboplatin on the incidence of ototoxicity, especially in the pediatric population, is not well characterized. Recent studies have demonstrated that the incidence of ototoxicity is higher than initially reported, particularly with higher dose carboplatin and when given after or concurrently with other ototoxic agents. 14, 15 Examination of pathologic specimens following carboplatin have shown damage to the cochlea's hair cells in the organ of Corti, 16 similar to the injury seen with cisplatin, aminoglycoside antibiotics, diuretics (eg furosemide), and noiseinduced injury. 17, 18 We report on a group of children with advanced stage neuroblastoma who sustained significant hearing loss after receiving high-dose carboplatin (2 g/m 2 , total dose) as part of their conditioning regimen for autologous bone marrow transplant (BMT).
Patients and methods

Patient selection
Fourteen children with advanced stage neuroblastoma underwent autologous BMT at the Children's Hospital/Dana Farber Cancer Institute between August 1992 and February 1994. Eleven of the 14 patients had audiograms at three time points -at diagnosis, prior to initiating treatment, pre-BMT and post-BMT -and thus, were evaluable for hearing loss. Three patients treated early in the course of this study received audiograms prior to and during primary chemotherapy treatment, but subsequently received additional platinum-containing chemotherapy without audiometric evaluation immediately prior to BMT. They were excluded from this report. As significant hearing loss emerged in this cohort of patients, the protocol was amended to require an audiogram immediately prior to BMT to allow an evaluation of the contribution of highdose carboplatin to hearing loss for these patients.
Informed consent was obtained for BMT prior to treatment according to the policies of the hospitals' institutional review boards (IRB). Ten of the 11 patients were enrolled on a protocol that had been previously reviewed and approved by Human Protection Committees at Children's Hospital and the Dana Farber Cancer Institute. The remaining patient was treated in an identical manner: individual therapy for this patient was approved by the IRB of both institutions. The protocol enrolled patients with stage III or stage IV neuroblastoma, greater than 1 year of age in complete or partial remission for consolidation with high-dose chemotherapy followed by stem cell rescue. All patients were prepared for autologous BMT with a three-drug regimen of chemotherapy, including etoposide 800 mg/m 2 /day via continuous infusion and carboplatin, 667 mg/m 2 /day for the first 3 days, followed by cyclophosphamide, 60 mg/kg/day for 2 days. After a rest day, all patients received stem cell support from immunomagnetically purged autologous marrow.
Audiometric methods
All 11 children underwent periodic otoscopic, tympanometric and audiometric evaluations. The method of evaluation varied with the child's age, state of health and ability to cooperate. Audiograms were characterized quantitatively based on hearing threshold levels at each tested frequency and by a grading system developed by Brock et al. 19 Audiometric evaluations: Four test methods were used to obtain audiograms. Auditory Brainstem Response (ABR) evoked potential threshold measures, Visual Reinforcement Audiometry (VRA), conditioned play audiometry, or conventional audiometry with a hand-raising response. ABR evaluation was used for baseline audiograms on two patients who were too ill/young to respond to localization tasks. The ABR evaluations consisted of threshold searches using 100 microsecond clicks as well as tone bursts at 1000, 2000 and 4000 Hz. To obtain the ABR, averaged electroencephalic responses were recorded via three scalp electrodes during chloral hydrate-induced sleep.
VRA was performed in a calibrated sound field or via earphones for children able to cooperate at a developmental level of 6 to 30 months. Sound-field (loudspeaker) measures yield the hearing levels of the better ear when an ear difference exists, and thus the poorer ear audiogram was unknown for children tested in the sound field. VRA in the sound field was used to evaluate frequencies 500-4000 Hz or 500-6000 Hz but not 8000 Hz. A warbled tone was most frequently used with a ±5% deviation around the selected center frequency. Occasionally, at the higher frequencies (4000 or 6000 Hz), pulsed pure tones were used. Conditioned play audiometry (ie placing a peg in a pegboard upon hearing a tone) was used for children able to cooperate at a developmental level of 30 months to 5 years. Conventional audiometry was used for older children.
Audiograms were categorized on the basis of the patient's better ear hearing which is the primary determinant of overall auditory performance. Better ear hearing status usually determines whether a patient may benefit from a hearing aid. Normal hearing for children is defined as normal threshold sensitivity (0-15 decibels hearing level or dBHL) for all frequencies tested (250-8000 Hz). 20 Thresholds greater than (poorer than) 15 dBHL in the frequency range 6000-8000 Hz constitute high frequency hearing loss (HFHL) which poses no significant impairment to spoken communication. Patients with HFHL may experience loss in the 'crisp' or brilliant quality to music or speech. Loss of hearing in the 2000-4000 Hz frequency range, however, results in an inability to discriminate consonant sounds and difficulty in recognizing words clearly in the presence of background noise. Patients having loss of hearing in the 2000-4000 Hz range, with normal hearing in the lower frequencies, may understand speech when spoken to directly, yet benefit from hearing aid use particularly in the language-learning years and in suboptimal listening conditions. Patients having speech frequency hearing loss (SFHL) in the 500-2000 Hz range require hearing aids for speech and language development and for ordinary communication.
Audiometric grading: The hearing status of study patients was graded according to Brock et al, 19 based on a threshold level of 40 dBHL at targeted frequencies of 1000 Hz, 2000 Hz, 4000 Hz and 8000 Hz. (Since the intermediate frequencies of 3000 Hz and 6000 Hz are not routinely tested, they were not included in the grading system.) The threshold of 40 dB HL was originally based on the observation by Brock and co-workers of the slope of hearing loss over the involved frequencies. The 40 dB HL represented the 'threshold shift' of impaired hearing frequencies below which the mean threshold levels were almost universally within normal limits. As noted, grades 3-4 represent SFHL with hearing loss involving the speech range frequencies of 1000 and 2000 Hz. Grades 1 and 2 represent loss in the higher frequencies of 4000 and 8000 Hz, while grade 0 represents Ͻ40 dB HL at all tested frequencies. It is important to note that grade 0 is not necessarily synonymous with 'normal hearing,' particulary if the threshold levels exceed 15 dB HL, as previously noted.
Renal function
The protocol was originally designed to include measures of creatinine clearance prior to the start of the conditioning regimen and a follow-up evaluation prior to hospital discharge. These measures, based on 24-h collections of voided urine proved to be technically difficult, particularly for young, diaper-clad patients. Newer isotope clearance techniques had not yet become standard practice during this study period. In the absence of measured creatinine clearance for all patients, serial serum creatinine levels were analyzed as markers of renal function, although the limitations of that method are fully recognized. 21 
Previous platinum exposure
Cisplatin equivalent units were calculated for each patient to quantify this cohort's cumulative exposure to platinumcontaining chemotherapy prior to and during BMT conditioning. 'Cisplatin equivalents' were derived as the sum of the cumulative cisplatin doses in mg/m 2 plus 25% of the cumulative carboplatin doses in mg/m 2 , according to Waterhouse et al. 22 
Statistical considerations
Clinical and laboratory data were collected and subsequently retrieved from the Children's Hospital/DFCI Bone Marrow Transplant database which contains clinical data on all bone marrow transplant recipients. Chart data prior to and during BMT were reviewed to assess risk factors of hearing loss including prior exposure to platinum compounds, exposure to aminoglycoside antibiotics and loop diuretics, and history of cranial irradiation. Descriptive statistics were used to summarize patient characteristics.
Results
Patient characteristics
Eleven patients, ranging in age from 1.1 years to 17.5 years at diagnosis were included in this analysis (see Table 1 ). There were five boys and six girls. The majority of patients had stage IV neuroblastoma; two patients had stage III disease. Prior to receiving BMT, all patients received multiagent chemotherapy based on the currently available treatment protocols at their respective institutions. These induction regimens varied in both the agents used as well as the dose size and dose rate of the two platinum-containing compounds, cisplatin and carboplatin. All 11 patients received cisplatin with a median cumulative dose of 400 mg/m 2 (range 200-800 mg/m 2 ) over a median of two cycles of the drug (range 1-6). Eight of the 11 patients also received carboplatin with cumulative doses ranging from 500 to 2000 mg/m 2 over one to two cycles. The median time interval between the last dose of a platinum-containing agent and the pre-BMT audiogram was 57 days, ranging from 43 to 175 days for those patients with documented deterioration in hearing post-BMT.
The majority of patients (n = 9) also received local radiation at cumulative doses of 2400 cGy to the primary tumor site(s) within the abdomen. One patient received 2400 cGy to the orbit in addition to abdominal irradiation. Two patients received no radiation. Patients were treated for a median time from diagnosis to autologous BMT of 7.3 months (range 5.6-11.1 months).
Audiometric results
All patients seen for audiometry at the time of diagnosis prior to the initiation of chemo-or radiotherapy had normal audiograms. Five patients were tested at audiometric frequencies to 8000 Hz, three at 6000 Hz but not at 8000 Hz, and four at 4000 Hz but not at 6000 or 8000 Hz. One patient had mild hearing loss in the worse hearing ear for the frequency 8000 Hz only.
The mean hearing thresholds of targeted frequencies for each of the three time periods are presented in Table 2 . The progression of hearing loss by patient is summarized in Table 1 . Immediately prior to BMT, two patients continued to have normal hearing at all frequencies tested in the better ear, although one of these patients was only tested at frequencies to 4000 Hz (grade 0). Six patients had high frequency hearing loss after completion of induction chemotherapy (three, grade 1; three, grade 2). Three patients had pre-BMT audiometry consistent with speech frequency hearing loss (grade 3), although only one of these patients was fitted for aids at the time of BMT. Following bone marrow transplant, all 11 patients had hearing loss in both ears ( Table 2 ). Eight of the nine patients had grade 3-4 loss. The remaining patient had grade 2 hearing loss, but because of the severity of hearing loss at the intermediate frequency of 3000 Hz, tested due to the patient's young age, biaural aids were recommended. In addition, hearing aids were recommended for all patients with grade 3 or 4 hearing loss. Symmetrical hearing loss was noted in all patients; no patient demonstrated a difference in hearing level greater than 15 dB between the better and worse ears at any frequency. Mean audiometric thresholds following BMT were 42 dB ± s.e. 7.7 dB at 2000 Hz and 67 db ± s.e. 5.5 dB at 8000 Hz in the better ear (see Figure 1) . The remaining two patients had grade 1 and grade 2 hearing loss, respectively.
Post-BMT audiograms were obtained at a mean of 74.8 days following re-infusion (median 72 days; range 11-184 days). Additionally, three children received audiograms 6 months or longer after the initial post-BMT test. These three long-term post-BMT tests were obtained at a mean of 19.3 months following re-infusion (median 22 months; range 9-27 months). The long-term post-BMT audiograms were compared with the initial post-BMT audiograms to determine whether the hearing loss noted post-BMT continued to deteriorate over time. Two of the three patient are without disease recurrence. Both of these children wear biaural aids and receive special educational services including speech and language therapy. The third patient with grade 1 hearing loss post-BMT is alive in relapse, having Values expressed as mean threshold in decibles (dB HL) with standard error in parentheses. All frequencies are reported in hertz (Hz).
had disease recurrence 4 years after BMT. Of the remaining eight patients, all of whom died of recurrent neuroblastoma, seven were fitted with hearing aids with subjective improvement in communication and adaption. Results of the available long-term post-BMT audiograms revealed no worsening of hearing levels in either ear when compared to the initial post-BMT audiograms (data not shown).
Other contributing risk factors
Renal status: In order to assess other possible risk factors for hearing loss, we analyzed renal function, exposure to nephrotoxins, and history of nephrectomy in all patients. These results are presented in Table 1 . Prior to BMT, serum creatinine levels were within the age-adjusted normal range for all patients, although the limitations of this approach are recognized. Seven of the 11 patients sustained significant changes in serum creatinine following carboplatin, ranging from 50% to over 100% of baseline levels. Changes in renal function occurred immediately following the carboplatin infusion prior to the receipt of autologous marrow ('day 0'), with subsequent return to normal serum creatinine levels prior to discharge. The remaining four patients had no change over normal baseline.
Exposure to nephrotoxins: Nephrotoxic antibiotics were administered following diagnosis as dictated by the clinical course of each patient. Four patients never received any aminoglycoside antibiotics. Of the remaining seven patients, three received gentamicin only during primary treatment (prior to BMT). None of the patients received aminoglycoside antibiotics or treatment with amphotericin during the conditioning period immediately prior to transplant. Of the four patients who received furosemide in the peritransplant period, only one patient received a prolonged course (14 days) to induce forced diuresis to maintain fluid balance in the setting of a single kidney. This patient had grade 1 ototoxicity prior to transplant which progressed to grade 4 ototoxicity following BMT. These data highlight the extent to which these patients were exposed to multiple potentially nephrotoxic agents, many of which are also known to cause hearing loss. The pattern of exposure, however, is extremely variable.
Discussion
This group of children with advanced stage neuroblastoma has a striking incidence of significant hearing loss with 81.8% requiring hearing aids following autologous BMT. The loss was noted within the first 6 months post transplant; the median time to ascertaining hearing loss was within 2 months. Hearing loss appeared to be stable over time. In the three patients who received audiograms during longterm follow-up examinations performed at an average of 19.3 months post-transplant, there was no evidence of either hearing improvement or further deterioration. The etiology of this severe hearing loss is difficult to define, given both the high incidence of significant hearing loss, the small cohort size, and the number of potentially contributing factors such as prior exposure to ototoxic agents and transiently compromised renal function. Nevertheless, the one consistent predictor of subsequent speech frequency hearing loss was the existence of high frequency hearing loss prior to BMT.
Our patients were heavily pre-treated with cisplatin and carboplatin, prior to receiving high-dose carboplatin as part of BMT conditioning regimen. The prior cumulative dose of platinum-containing chemotherapy is a well-established risk factor for hearing loss. [11] [12] [13] Weatherly and co-workers 11 reported that both the proportion of children who demonstrated hearing loss and the severity of that loss increased with successive dosing of cisplatin. Skinner et al 12 also noted a greater degree of hearing loss in children and adolescents as the cumulative dose increased, but found a 'plateau' phenomenon with no further deterioration at cumulative doses Ͼ600 mg/m 2 . McHaney and co-workers 13 reported an 88% incidence of high frequency hearing loss in patients receiving Ͼ450 mg/m 2 of cisplatin and speech frequency hearing loss when total doses exceeded 990 mg/m 2 .
In contrast to the well-reported association between the cumulative dose of cisplatin and ototoxicity, little has been reported on the effect of the cumulative dose of carboplatin on hearing loss. Kennedy et al 15 reported on a group of adults with hearing loss only involving the high frequency range. He found that the incidence of hearing loss increased with cumulative doses, although it could also occur in an idiosyncratic manner after a single dose. Macdonald et al 23 also found hearing loss to generally increase in children with increasing doses, but also noted variations in individual susceptibility with some patients exhibiting high frequency hearing loss after a single dose. In a phase I doseescalation study, Elias et al 24 reported 'moderate' hearing loss in three of four patients treated at a dose level of 1600 mg/m 2 of carboplatin; none of these patients had prior cisplatin exposure. Prior reports of the preparative regimen for ABMT used in our study have not been associated with hearing loss, although most of the patients were not heavily pre-treated with platinum agents and were older than our study patients (Wiley, personal communication). A recent study by Freilich and co-workers 25 of a small cohort of children receiving experimental treatment for malignant brain tumors reports deterioration of hearing in five of the 11 patients following consolidation therapy including highdose carboplatin. Of note, seven of the 11 patients had highfrequency hearing loss following induction therapy with cisplatin. Our data confirm that carboplatin-associated ototoxicity may be more prevalent than previously reported, especially in a cohort with significant previous exposure to platinum compounds. As high-dose consolidation with carboplatin becomes increasingly commonplace in pediatric oncology protocols, the importance of this side-effect of therapy must be underlined.
The prior or concurrent use of other ototoxic agents may also have contributed to hearing loss in our population, although given the widespread exposure to these agents and the high incidence of hearing loss, the specific contribution is difficult to prove. The majority of patients received aminoglycoside antibiotics (eg gentamicin) and/or diuretics (eg furosemide) at some time during their course. Results of multiple animal studies involving rhesus monkeys, guinea pigs and mice have demonstrated that, like cisplatin, these agents induce damage to the cochlear hair cells at the basal end of the organ of Corti. 5, 8, 13 Renal compromise prior to BMT from chemotherapy, surgery, local radiotherapy or ototoxic antibiotics was not apparent in our patients. During the conditioning period, however, more than half of the patients developed transient renal insufficiently following carboplatin, as indicated by a rise in serum creatinine. The relationship between renal impairment and increased toxicity for carboplatin is thought to be secondary to delayed renal excretion. Egorin et al 26 and Calvert and his co-workers 27 have suggested that toxicity can be predicted by renal function -notably creatinine clearance. Dose reduction based on creatinine clearance (area under the curve (AUC) dosing) as well as factoring in a history of prior chemotherapy have been proposed as strategies to minimize toxicity.
The extent of functional disability due to speech range hearing loss in our cohort of patients highlights the need for further efforts to both monitor and possibly minimize this complication. This is especially significant as higher doses of platinum compounds continue to be used in an attempt to cure patients with high-risk tumors, and bone marrow transplantation and high-dose chemotherapy with stem cell rescue obviate previous dose-limiting toxicities. Given the almost certain deterioration in hearing following high-dose carboplatin, the most important intervention would be the close screening of hearing during primary therapy. Judicious use of potentially ototoxic agents and strategies to minimize noise exposure should also be considered. Dosing modifications of high-dose carboplatin (AUC dosing) 27 may impact on the incidence of ototoxicity, but this has not been formally studied in the pediatric population. Novel applications of chemoprotectants, such as amifostine, should be considered in future studies.
In cases where hearing loss is inevitable due to cumulative ototoxic exposures, families should be apprised of and prepared for the drawbacks and tradeoffs of potentially curable therapy, and children should be offered therapeutic intervention to stimulate the development of speech, language and listening skills. Moreover, caregivers and families must be educated about the benefits and limitations of hearing aids. Specifically, while hearing aids may greatly improve language acquisition, social interaction, and personal adaption, they are not a panacea. In contrast to prescription lenses, hearing aids do not correct for sensorineural hearing loss, but rather serve a function similar to low vision aids by amplification of all sound. Specialized educational service for hearing impairment may be necessary in addition to preferential classroon seating, and speech and language therapy.
